Your browser doesn't support javascript.
Seroprevalence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in Kenya.
Etyang, Anthony O; Lucinde, Ruth; Karanja, Henry; Kalu, Catherine; Mugo, Daisy; Nyagwange, James; Gitonga, John; Tuju, James; Wanjiku, Perpetual; Karani, Angela; Mutua, Shadrack; Maroko, Hosea; Nzomo, Eddy; Maitha, Eric; Kamuri, Evanson; Kaugiria, Thuranira; Weru, Justus; Ochola, Lucy B; Kilimo, Nelson; Charo, Sande; Emukule, Namdala; Moracha, Wycliffe; Mukabi, David; Okuku, Rosemary; Ogutu, Monicah; Angujo, Barrack; Otiende, Mark; Bottomley, Christian; Otieno, Edward; Ndwiga, Leonard; Nyaguara, Amek; Voller, Shirine; Agoti, Charles N; Nokes, David James; Ochola-Oyier, Lynette Isabella; Aman, Rashid; Amoth, Patrick; Mwangangi, Mercy; Kasera, Kadondi; Ng'ang'a, Wangari; Adetifa, Ifedayo M O; Wangeci Kagucia, E; Gallagher, Katherine; Uyoga, Sophie; Tsofa, Benjamin; Barasa, Edwine; Bejon, Philip; Scott, J Anthony G; Agweyu, Ambrose; Warimwe, George M.
  • Etyang AO; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Lucinde R; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Karanja H; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Kalu C; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Mugo D; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Nyagwange J; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Gitonga J; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Tuju J; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Wanjiku P; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Karani A; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Mutua S; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Maroko H; KEMRI Center for Infectious and Parasitic Diseases Control Research, Alupe, Kenya.
  • Nzomo E; Kilifi County Hospital, Kilifi, Kenya.
  • Maitha E; Department of Health, Kilifi County, Kenya.
  • Kamuri E; Kenyatta National Hospital, Nairobi, Kenya.
  • Kaugiria T; Kenyatta National Hospital, Nairobi, Kenya.
  • Weru J; Kenyatta National Hospital, Nairobi, Kenya.
  • Ochola LB; Alupe Sub-County Hospital, Busia, Kenya.
  • Kilimo N; Institute of Primate Research, Nairobi, Kenya.
  • Charo S; Kocholia Sub-County Hospital, Busia, Kenya.
  • Emukule N; Busia County Referral Hospital, Busia, Kenya.
  • Moracha W; Department of Health, Busia County, Busia, Kenya.
  • Mukabi D; Department of Health, Busia County, Busia, Kenya.
  • Okuku R; Department of Health, Busia County, Busia, Kenya.
  • Ogutu M; Department of Health, Busia County, Busia, Kenya.
  • Angujo B; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Otiende M; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Bottomley C; Department of Infectious Diseases Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Otieno E; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Ndwiga L; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Nyaguara A; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Voller S; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Agoti CN; Department of Infectious Diseases Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Nokes DJ; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Ochola-Oyier LI; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Aman R; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Amoth P; Ministry of Health, Government of Kenya, Nairobi, Kenya.
  • Mwangangi M; Ministry of Health, Government of Kenya, Nairobi, Kenya.
  • Kasera K; Ministry of Health, Government of Kenya, Nairobi, Kenya.
  • Ng'ang'a W; Ministry of Health, Government of Kenya, Nairobi, Kenya.
  • Adetifa IMO; Presidential Policy and Strategy Unit, The Presidency, Government of Kenya, Nairobi, Kenya.
  • Wangeci Kagucia E; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Gallagher K; Department of Infectious Diseases Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Uyoga S; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Tsofa B; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Barasa E; Department of Infectious Diseases Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Bejon P; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Scott JAG; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Agweyu A; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Warimwe GM; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Clin Infect Dis ; 74(2): 288-293, 2022 01 29.
Article in English | MEDLINE | ID: covidwho-1662110
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT

BACKGROUND:

Few studies have assessed the seroprevalence of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among healthcare workers (HCWs) in Africa. We report findings from a survey among HCWs in 3 counties in Kenya.

METHODS:

We recruited 684 HCWs from Kilifi (rural), Busia (rural), and Nairobi (urban) counties. The serosurvey was conducted between 30 July and 4 December 2020. We tested for immunoglobulin G antibodies to SARS-CoV-2 spike protein, using enzyme-linked immunosorbent assay. Assay sensitivity and specificity were 92.7 (95% CI, 87.9-96.1) and 99.0% (95% CI, 98.1-99.5), respectively. We adjusted prevalence estimates, using bayesian modeling to account for assay performance.

RESULTS:

The crude overall seroprevalence was 19.7% (135 of 684). After adjustment for assay performance, seroprevalence was 20.8% (95% credible interval, 17.5%-24.4%). Seroprevalence varied significantly (P < .001) by site 43.8% (95% credible interval, 35.8%-52.2%) in Nairobi, 12.6% (8.8%-17.1%) in Busia and 11.5% (7.2%-17.6%) in Kilifi. In a multivariable model controlling for age, sex, and site, professional cadre was not associated with differences in seroprevalence.

CONCLUSION:

These initial data demonstrate a high seroprevalence of antibodies to SARS-CoV-2 among HCWs in Kenya. There was significant variation in seroprevalence by region, but not by cadre.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Observational study / Prognostic study Limits: Humans Country/Region as subject: Africa Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: Cid

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Observational study / Prognostic study Limits: Humans Country/Region as subject: Africa Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: Cid